Your Article Summary
See Latest ArticlesA phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura
International Journal of Hematology, 06/26/09
Shirasugi Y et al. - No binding antibodies to romiplostim or thrombopoietin were detected. Romiplostim is safe and well tolerated in Japanese patients with chronic ITP and is effective in producing platelet count increases, consistent with the results from studies in non-Japanese patients. On the basis of these findings, a starting dose of 3ug/kg was recommended for phase III evaluation of romiplostim in Japanese patients with chronic ITP.
Related Articles
Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura
International Journal of Hematology, 10/12/09
Relevance Score: 70%
Immune thrombocytopenia associated with Mycoplasma pneumoniae infection: a case report and review of literature
Blood Coagulation & Fibrinolysis, 10/07/09
Relevance Score: 68%
Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia
International Journal of Hematology, 10/13/09
Relevance Score: 67%
Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura
Blood, 10/02/09
Relevance Score: 67%
Romiplostim in chronic immune thrombocytopenic purpura
Clinical Therapeutics, 10/23/09
Relevance Score: 66%
Today in Coagulation/Bleeding Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Intracranial Hemorrhage in Acute and Chronic Childhood Immune Thrombocytopenic Purpura over a Ten-Year Period: An Egyptian Multicenter Study
Acta Haematologica, 12/04/09
Hematological Issues in Critically Ill Patients with Cancer
Critical Care Clinics, 12/04/09
Pharmacokinetics and safety of fibrinogen concentrate
Journal of Thrombosis and Haemostasis, 12/03/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09